Education
About Us
Working with TipRanks
Follow Us
Genprex Inc (GNPX)
NASDAQ:GNPX
Atezolizumab, Quaratusugene Ozeplasmid
Small Cell Lung Cancer Extensive Stage
Phase I/II
Recruiting
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Jan 19, 2023
―
Pembrolizumab, Docetaxel, Ramucirumab, Quaratusugene Ozeplasmid, Investigator's Treatment Of Choice
Non Small Cell Lung Cancer
Phase I/II
Terminated
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer
Sep 20, 2021
―
Osimertinib, Platinum-Based Chemotherapy, Quaratusugene Ozeplasmid
Carcinoma, Non-Small Cell Lung
Phase I/II
Recruiting
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Jul 22, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Genprex Inc (GNPX) have in its pipeline
GNPX is currently developing the following drugs: Atezolizumab, Quaratusugene Ozeplasmid, Pembrolizumab, Docetaxel, Ramucirumab, Quaratusugene Ozeplasmid, Investigator's Treatment Of Choice, Osimertinib, Platinum-Based Chemotherapy, Quaratusugene Ozeplasmid. These drug candidates are in various stages of clinical development as the company works toward FDA approval.